Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15854195 | 1.00 | ALDH1A1 (0.70) | ALDH1A1KMT2ALMNAEGFRL3MBTL1 | |
| SCHEMBL15854226 | 0.84 | KMT2A (0.53) | ALDH1A1KMT2ALMNAGAASMN1; SMN2 | |
| SCHEMBL17219731 | 0.84 | KMT2A (0.53) | ALDH1A1KMT2ALMNAGAASMN1; SMN2 | |
| SCHEMBL22196883 | 0.83 | KMT2A (1.00) | ALDH1A1KMT2ALMNAEGFRL3MBTL1 | |
| SCHEMBL18219883 | 0.78 | KMT2A (0.69) | ALDH1A1KMT2ALMNAL3MBTL1GAA | |
| SCHEMBL20306892 | 0.77 | ALDH1A1 (0.67) | ALDH1A1KMT2ALMNAEGFRL3MBTL1 | |
| SCHEMBL17219490 | 0.77 | SMN1; SMN2 (0.84) | ALDH1A1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL15854259 | 0.77 | SMN1; SMN2 (0.84) | ALDH1A1KMT2ALMNASMN1; SMN2KDM4E | |
| SCHEMBL18219899 | 0.75 | KMT2A (0.65) | ALDH1A1KMT2ALMNAEGFRGAA | |
| SCHEMBL17120722 | 0.75 | KMT2A (0.62) | ALDH1A1KMT2ALMNAEGFRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540338-B2 | Substituted cinnamic acid amides for treating pain | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20150322024-A1 | Cinnamic Acid Amide Derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2015-11-12 | — | — | US | disclosed |
| EP-2940003-A1 | CINNAMIC ACID AMIDE DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322024-A1 | Cinnamic Acid Amide Derivative | OPRL1, TRPV1, TRPA1 | ALDH1A1 350/4885KMT2A 1648/4885LMNA 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.